Causes of death after unrelated bone marrow (UBMT), T-cell–depleted unrelated bone marrow (T-UBMT), and unrelated cord blood transplants (UCBT) before and after day 100 posttransplant
| Causes . | UBMT . | T-UBMT . | UCBT . | |||
|---|---|---|---|---|---|---|
| < 100 days N = 56 . | ≥ 100 days N = 77 . | < 100 days N = 37 . | ≥ 100 days N = 67 . | < 100 days N = 43 . | ≥ 100 days N = 20 . | |
| Relapse or progression | 7 (12.5%) | 55 (71.4% | 12 (32.5%) | 48 (71.5%) | 5 (11.6%) | 14 (70%) |
| Transplantation-related causes | 49 (87.5%) | 22 (28.6%) | 25 (67.5%) | 19 (28.5%) | 38 (88.4%) | 6 (30%) |
| GVHD | 18 (31.5%) | 5 (6.5%) | 3 (8%) | 6 (9%) | 6 (14%) | 0 |
| Toxicity6-150 | 12 (21%) | 5 (6.5%) | 7 (19%) | 0 | 9 (21%) | 3 (15%) |
| Hemorrhage | 0 | 1 (1.3%) | 1 (2.7%) | 0 | 0 | 0 |
| Rejection | 0 | 0 | 2 (5.4%) | 2 (3%) | 4 (9.3%) | 0 |
| Bacterial infection | 3 (5%) | 2 (2.6%) | 2 (5.4%) | 2 (3%) | 4 (9.3%) | 0 |
| Viral infection | 4 (7%) | 5 (6.5%) | 5 (13.5%) | 3 (4.5%) | 8 (18.6%) | 1 (5%) |
| EBV lymphoma | 2 (3.5%) | 0 | 2 (5.4%) | 1 (1.5%) | 0 | 1 (5%) |
| Fungal infection | 9 (16%) | 1 (1.3%) | 2 (5.4%) | 2 (3%) | 4 (9.3%) | 0 |
| Parasitic infection | 0 | 0 | 0 | 0 | 1 (2.3%) | 0 |
| Unknown | 2 (3.5%) | 3 (3.9%) | 1 (2.7%) | 3 (4.5%) | 2 (4.6%) | 1 (5%) |
| Causes . | UBMT . | T-UBMT . | UCBT . | |||
|---|---|---|---|---|---|---|
| < 100 days N = 56 . | ≥ 100 days N = 77 . | < 100 days N = 37 . | ≥ 100 days N = 67 . | < 100 days N = 43 . | ≥ 100 days N = 20 . | |
| Relapse or progression | 7 (12.5%) | 55 (71.4% | 12 (32.5%) | 48 (71.5%) | 5 (11.6%) | 14 (70%) |
| Transplantation-related causes | 49 (87.5%) | 22 (28.6%) | 25 (67.5%) | 19 (28.5%) | 38 (88.4%) | 6 (30%) |
| GVHD | 18 (31.5%) | 5 (6.5%) | 3 (8%) | 6 (9%) | 6 (14%) | 0 |
| Toxicity6-150 | 12 (21%) | 5 (6.5%) | 7 (19%) | 0 | 9 (21%) | 3 (15%) |
| Hemorrhage | 0 | 1 (1.3%) | 1 (2.7%) | 0 | 0 | 0 |
| Rejection | 0 | 0 | 2 (5.4%) | 2 (3%) | 4 (9.3%) | 0 |
| Bacterial infection | 3 (5%) | 2 (2.6%) | 2 (5.4%) | 2 (3%) | 4 (9.3%) | 0 |
| Viral infection | 4 (7%) | 5 (6.5%) | 5 (13.5%) | 3 (4.5%) | 8 (18.6%) | 1 (5%) |
| EBV lymphoma | 2 (3.5%) | 0 | 2 (5.4%) | 1 (1.5%) | 0 | 1 (5%) |
| Fungal infection | 9 (16%) | 1 (1.3%) | 2 (5.4%) | 2 (3%) | 4 (9.3%) | 0 |
| Parasitic infection | 0 | 0 | 0 | 0 | 1 (2.3%) | 0 |
| Unknown | 2 (3.5%) | 3 (3.9%) | 1 (2.7%) | 3 (4.5%) | 2 (4.6%) | 1 (5%) |
Including interstitial pneumonitis, veno-occlusive disease, cardiac toxicity, and Acute Respiratory Distress Syndrome.